EUVIMEDObjevte EUVIMED
CrossrefInformační karta

Impact of Phenotype on Recurrence of VT Post‐Ablation in Patients With Nonischemic Cardiomyopathy

Shreyas Singireddy, Sami Shoura, Darshine Venugopal, Christopher Chinnatambi, Siddharth Shah, Christopher Sparrow, Timir Baman, Amit Mehrotra

Pacing and Clinical Electrophysiology · 2026-11 · 49 (11) · 1676-1684

DOI: 10.1111/pace.70340 ↗
AbstraktBibliografické údaje

Abstrakt

ABSTRACT Background Ventricular tachycardia (VT) ablation outcomes in nonischemic cardiomyopathy (NICM) may differ by disease phenotype, but prior studies have pooled NICM as a single entity. We performed a phenotype‐stratified meta‐analysis of VT ablation outcomes across six major NICM subtypes. Methods We systematically searched PubMed, Embase, and the Cochrane Library through January 2026. Studies were stratified by phenotype: lamin A/C (LMNA), cardiac sarcoidosis, dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), myocarditis, and arrhythmogenic right ventricular cardiomyopathy (ARVC). The primary outcome was VT recurrence. Proportions were pooled using restricted maximum likelihood estimation on the logit scale. Phenotype differences were tested via mixed‐effects meta‐regression. Results Eighteen studies (1699 patients) met inclusion criteria after rigorous center‐level overlap resolution. VT recurrence differed significantly across phenotypes (F [5,12] = 3.78, p = 0.027). LMNA had the highest recurrence (82.6%; 95% CI 51.6%–95.5%; k = 5), followed by sarcoidosis (57.1%; 32.2%–78.8%; k = 2), DCM (42.7%; 24.1%–63.6%; k = 4), HCM (36.2%; 23.8%–50.7%; k = 2), myocarditis (34.5%; 27.3%–42.5%; k = 2), and ARVC (33.8%; 16.0%–57.9%; k = 3). Phenotype explained 44.7% of between‐study heterogeneity. Conclusions VT ablation outcomes in NICM varied by the underlying disease phenotype, with recurrence rates ranging from 82.6% in LMNA cardiomyopathy to 33.8% in ARVC. These hypothesis‐generating findings argue against treating NICM as a unified category and provide a foundation for phenotype‐specific procedural counseling and clinical trial stratification that warrants validation in prospective registries.

Znalosti, které odpovídají vaší práci.

Od bezplatného začátku přes osobní rešerše literatury až po kompletní Research Suite.

Zobrazit tarify →

Jsou zahrnuty všechny plné texty vydavatelů?

Ne. Bibliografické záznamy, abstrakty a plné texty jsou různé typy obsahu. To, zda je plný text dostupný, závisí na zdroji, Open Access a vašich stávajících licencích. Tarif EUVIMED nenahrazuje dodatečná vydavatelská práva.

Zobrazit tarify →